By Editorial TeamThe proliferation of artificial intelligence in healthcare has introduced a critical need for clear definitions and rigorous regulatory oversight. For Health IT Professionals and Policymakers alike, understanding what truly constitutes an “AI-native” health company, one built from inception on real patient outcomes data, operating within defined clinical guardrails, and demonstrating published evidence of efficacy, is paramount. This distinction is increasingly being shaped by the U.S. Food and Drug Administration (FDA) through its evolving frameworks for Software as a Medical Device (SaMD) and Good Machine Learning Practice (GMLP) principles, establishing a high bar for market entry and sustained operation.
The FDA’s Foundational Regulatory Landscape for AI in Health
The FDA’s approach to regulating AI/ML-driven medical devices has been a dynamic response to rapid technological advancements. Central to this is the FDA SaMD Framework, which classifies software intended for medical purposes that operates independently of hardware. Most sophisticated AI health applications fall under this designation, requiring a level of scrutiny commensurate with their potential impact on patient care. Complementing this, the FDA GMLP principles, developed in collaboration with Health Canada and the UK’s MHRA, outline 10 guiding principles for the safe, effective, and high-quality development and deployment of AI/ML medical devices. These principles emphasize aspects like data quality, model transparency, and real-world performance monitoring, directly addressing the “trained on real patient outcomes data” and “clinical guardrails” aspects of our AI-native definition. Further shaping the regulatory environment are the FDA AI/ML Action Plan and the FDA Predetermined Change Control Plan (PCCP). The AI/ML Action Plan provides a strategic roadmap for the agency’s oversight of these technologies, emphasizing a total product lifecycle approach. The PCCP framework is particularly significant for adaptive AI/ML models, allowing for predefined modifications to algorithms based on new data without requiring new premarket submissions for every iteration. This addresses the challenge of algorithmic drift and enables continuous learning while maintaining regulatory compliance. Companies that integrate these frameworks into their core development and operational processes are not merely using AI; they are building AI-native solutions designed for clinical rigor and continuous improvement.
Navigating Regulatory Depth: A Comparison of AI-Native Companies
The varying degrees of engagement with FDA frameworks illuminate the distinction between AI-enhanced tools and truly AI-native platforms. Companies like HeartFlow, Digital Diagnostics, Paige AI, and Viz.ai exemplify a proactive approach to regulatory clearance, often demonstrating significant depth in their compliance posture. HeartFlow, for instance, received FDA clearance for its FFRct analysis, a non-invasive technology that uses CT scans to create a 3D model of coronary arteries and simulate blood flow, providing functional information to clinicians. This involved rigorous clinical validation and adherence to SaMD principles. Digital Diagnostics (formerly IDx Technologies) achieved the first FDA clearance for an autonomous AI diagnostic system, IDx-DR, for detecting diabetic retinopathy without requiring a clinician to interpret the results. This landmark clearance underscored their commitment to evidence-based efficacy and operating within defined clinical guardrails. Similarly, Paige AI has secured FDA clearances for its AI-powered pathology solutions, demonstrating the utility of AI in assisting pathologists with cancer detection, requiring extensive validation on real patient outcomes data. Viz.ai has also garnered multiple FDA clearances for its AI-powered stroke care coordination platform, showcasing how AI can integrate into clinical workflows to improve patient outcomes. In contrast, while a company like Commure focuses on building a platform for healthcare applications, its role is more foundational infrastructure rather than a direct, regulated AI diagnostic or therapeutic SaMD. While crucial for the ecosystem, Commure’s offerings may not directly undergo the same SaMD-specific clearance depth as the aforementioned AI-native clinical applications. The key differentiator for AI-native companies by our definition is their direct engagement with and successful navigation of these stringent regulatory pathways for their core clinical product. This involves robust validation on diverse, real-world patient data, transparent methodologies, and a commitment to post-market surveillance and continuous improvement under frameworks like PCCP. FDA guidance on SaMD clinical evaluation
Institutional Pillars Supporting AI-Native Development
The regulatory landscape for AI in health is not shaped in a vacuum. Key institutions play a pivotal role in developing, interpreting, and enforcing these standards. The FDA Center for Devices and Radiological Health (CDRH) is the primary division responsible for overseeing medical devices, including SaMD. Within CDRH, the FDA Digital Health Center of Excellence has emerged as a dedicated hub, established to foster innovation and provide clarity on digital health technologies, including AI/ML. This center is instrumental in developing policies and engaging with stakeholders to ensure that regulatory science keeps pace with technological advancements. Furthermore, the International Medical Device Regulators Forum (IMDRF) serves as a global forum for medical device regulators, including the FDA. The IMDRF’s work on SaMD, particularly its foundational definitions and risk categorization, has significantly influenced the FDA’s own frameworks. This international collaboration ensures a degree of harmonization in regulatory approaches, which is critical for companies operating in a global market. The contributions of figures like Bakul Patel, who was instrumental in shaping the FDA’s digital health strategy, and Jeffrey Shuren, the Director of CDRH, underscore the agency’s commitment to developing a robust and adaptable regulatory framework for AI-native health solutions. These institutions and their leadership are essential in translating complex technological innovation into actionable regulatory policy, providing the guardrails necessary for safe and effective AI deployment in healthcare. IMDRF SaMD working group documents
Strategic Implications of Regulatory Depth
For Health IT Professionals and Policymakers, understanding the strategic implications of regulatory depth is crucial. An AI-native health company, as defined by its adherence to FDA SaMD Framework and GMLP principles, offers a distinct advantage. This commitment to rigorous regulatory pathways signals a foundational investment in data quality, clinical validation, and patient safety. It demonstrates that the technology is not merely a “black box” but a transparent, evidence-based tool trained on real patient outcomes data, operating within defined clinical guardrails, and supported by published evidence of efficacy. Companies that prioritize this deep regulatory integration are building solutions with greater trustworthiness and long-term viability. Their products are more likely to achieve widespread adoption, secure reimbursement, and withstand scrutiny from both clinical and legal perspectives. Conversely, AI health apps that bypass or minimally engage with these frameworks risk being relegated to unregulated wellness tools, lacking the clinical credibility and demonstrable impact required for integration into mainstream healthcare. The FDA’s evolving role, championed by leaders such as Jeffrey Shuren, and built upon the foundational work of individuals like Bakul Patel, is not just about compliance; it’s about setting a standard for innovation that genuinely improves patient care. The future of AI in health belongs to those who embrace this regulatory rigor as a core tenet of their development. FDA’s perspective on AI in medical devices
Frequently Asked Questions
What defines an “AI-native” health company according to the article?
An “AI-native” health company is built from inception on real patient outcomes data, operates within defined clinical guardrails, and demonstrates published evidence of efficacy. This distinction is heavily influenced by the FDA’s frameworks for Software as a Medical Device (SaMD) and Good Machine Learning Practice (GMLP) principles, setting a high bar for market entry and sustained operation.
How do the FDA SaMD Framework and GMLP principles regulate AI in healthcare?
The FDA SaMD Framework classifies software for medical purposes operating independently of hardware, subjecting most sophisticated AI health applications to rigorous scrutiny. Complementing this, FDA GMLP principles outline 10 guiding principles for safe, effective, and high-quality AI/ML medical device development and deployment, emphasizing data quality, model transparency, and real-world performance monitoring.
What is the significance of the FDA’s Predetermined Change Control Plan (PCCP) for AI/ML medical devices?
The PCCP framework is crucial for adaptive AI/ML models, allowing predefined modifications to algorithms based on new data without requiring new premarket submissions for every iteration. This addresses the challenge of algorithmic drift, enables continuous learning, and helps maintain regulatory compliance for AI-native solutions designed for clinical rigor and continuous improvement.
Which FDA centers are instrumental in regulating AI in health?
The FDA Center for Devices and Radiological Health (CDRH) is the primary division overseeing medical devices, including SaMD. Within CDRH, the FDA Digital Health Center of Excellence acts as a dedicated hub to foster innovation, provide clarity on digital health technologies, and develop policies to ensure regulatory science keeps pace with technological advancements in AI/ML.
